Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Schizophrenia | 16 | 2021 | 324 | 2.340 |
Why?
|
| Schizophrenic Psychology | 6 | 2021 | 81 | 1.270 |
Why?
|
| Transcranial Direct Current Stimulation | 4 | 2024 | 21 | 1.200 |
Why?
|
| Transcranial Magnetic Stimulation | 6 | 2025 | 77 | 1.110 |
Why?
|
| Cognition | 6 | 2024 | 829 | 0.900 |
Why?
|
| Th17 Cells | 2 | 2022 | 101 | 0.860 |
Why?
|
| Psoriasis | 2 | 2022 | 48 | 0.850 |
Why?
|
| Transcription, Genetic | 2 | 2018 | 1363 | 0.710 |
Why?
|
| Skin Neoplasms | 3 | 2024 | 909 | 0.700 |
Why?
|
| Psychotic Disorders | 3 | 2020 | 146 | 0.700 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2018 | 750 | 0.660 |
Why?
|
| Hospitals, Psychiatric | 2 | 2018 | 70 | 0.650 |
Why?
|
| Transcriptome | 3 | 2022 | 1103 | 0.620 |
Why?
|
| Patient Admission | 2 | 2018 | 185 | 0.600 |
Why?
|
| Brain | 10 | 2023 | 3175 | 0.600 |
Why?
|
| Self Administration | 1 | 2019 | 49 | 0.590 |
Why?
|
| APOBEC Deaminases | 1 | 2018 | 7 | 0.570 |
Why?
|
| Cytosine Deaminase | 1 | 2018 | 15 | 0.570 |
Why?
|
| Mutation Rate | 2 | 2018 | 68 | 0.560 |
Why?
|
| Epidermis | 1 | 2018 | 62 | 0.560 |
Why?
|
| Gamma Rhythm | 3 | 2015 | 11 | 0.550 |
Why?
|
| Epidermolysis Bullosa Dystrophica | 1 | 2018 | 46 | 0.520 |
Why?
|
| Safety-net Providers | 1 | 2018 | 93 | 0.510 |
Why?
|
| Mood Disorders | 1 | 2018 | 129 | 0.510 |
Why?
|
| Psychomotor Performance | 1 | 2018 | 174 | 0.510 |
Why?
|
| Pain Management | 1 | 2019 | 205 | 0.490 |
Why?
|
| Osteoarthritis, Knee | 1 | 2019 | 282 | 0.460 |
Why?
|
| DNA Repair | 2 | 2018 | 571 | 0.450 |
Why?
|
| Single-Cell Analysis | 1 | 2018 | 350 | 0.440 |
Why?
|
| Inflammation | 2 | 2022 | 1489 | 0.440 |
Why?
|
| Heterochromatin | 1 | 2014 | 52 | 0.430 |
Why?
|
| Afferent Pathways | 1 | 2013 | 10 | 0.410 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 512 | 0.410 |
Why?
|
| Decision Making | 1 | 2019 | 726 | 0.400 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 712 | 0.380 |
Why?
|
| Young Adult | 15 | 2025 | 10103 | 0.360 |
Why?
|
| Neuropsychological Tests | 7 | 2021 | 960 | 0.310 |
Why?
|
| Cognition Disorders | 2 | 2016 | 556 | 0.310 |
Why?
|
| Humans | 40 | 2025 | 131163 | 0.290 |
Why?
|
| Skin | 2 | 2022 | 545 | 0.290 |
Why?
|
| Mutation | 2 | 2019 | 6099 | 0.270 |
Why?
|
| Male | 25 | 2025 | 64957 | 0.270 |
Why?
|
| Genome, Human | 1 | 2014 | 1321 | 0.260 |
Why?
|
| Adult | 20 | 2025 | 31282 | 0.260 |
Why?
|
| Brain Mapping | 4 | 2018 | 384 | 0.260 |
Why?
|
| Electroencephalography | 7 | 2020 | 863 | 0.250 |
Why?
|
| Temporal Lobe | 3 | 2018 | 110 | 0.240 |
Why?
|
| Aging | 1 | 2013 | 1242 | 0.240 |
Why?
|
| Female | 23 | 2025 | 70963 | 0.230 |
Why?
|
| Cognitive Dysfunction | 2 | 2021 | 338 | 0.210 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2024 | 15 | 0.210 |
Why?
|
| gamma-Aminobutyric Acid | 3 | 2015 | 167 | 0.210 |
Why?
|
| Hippocampus | 2 | 2021 | 806 | 0.210 |
Why?
|
| Memory, Short-Term | 3 | 2020 | 138 | 0.210 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 1 | 2025 | 131 | 0.190 |
Why?
|
| Dopamine | 2 | 2016 | 246 | 0.190 |
Why?
|
| Electromagnetic Fields | 1 | 2022 | 24 | 0.180 |
Why?
|
| Antipsychotic Agents | 3 | 2018 | 375 | 0.180 |
Why?
|
| Time Factors | 4 | 2018 | 6196 | 0.180 |
Why?
|
| Memory Disorders | 2 | 2021 | 204 | 0.170 |
Why?
|
| Analysis of Variance | 2 | 2013 | 928 | 0.170 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 463 | 0.170 |
Why?
|
| Middle Aged | 9 | 2025 | 28601 | 0.170 |
Why?
|
| Inflammation Mediators | 1 | 2022 | 226 | 0.170 |
Why?
|
| Mutagenesis | 2 | 2020 | 324 | 0.170 |
Why?
|
| Karyotype | 1 | 2020 | 30 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 265 | 0.160 |
Why?
|
| Chromosomal Instability | 1 | 2020 | 59 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 2026 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2024 | 768 | 0.140 |
Why?
|
| RNA | 1 | 2022 | 517 | 0.140 |
Why?
|
| Foreskin | 1 | 2018 | 4 | 0.140 |
Why?
|
| Amphiregulin | 1 | 2018 | 13 | 0.140 |
Why?
|
| Cell Aggregation | 1 | 2018 | 20 | 0.140 |
Why?
|
| S100 Proteins | 1 | 2018 | 40 | 0.140 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2019 | 89 | 0.140 |
Why?
|
| Hair Follicle | 1 | 2018 | 31 | 0.140 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2018 | 16 | 0.140 |
Why?
|
| Keratinocytes | 1 | 2018 | 71 | 0.140 |
Why?
|
| Sex Distribution | 1 | 2019 | 318 | 0.140 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2019 | 97 | 0.140 |
Why?
|
| Adolescent | 8 | 2025 | 20987 | 0.140 |
Why?
|
| Executive Function | 1 | 2019 | 122 | 0.140 |
Why?
|
| Mental Health Services | 2 | 2019 | 285 | 0.140 |
Why?
|
| Interleukin-3 | 1 | 2018 | 16 | 0.140 |
Why?
|
| Cholinergic Antagonists | 1 | 2018 | 46 | 0.140 |
Why?
|
| Adolescent Development | 1 | 2018 | 29 | 0.140 |
Why?
|
| Prefrontal Cortex | 2 | 2018 | 215 | 0.130 |
Why?
|
| Cerebral Cortex | 3 | 2016 | 445 | 0.130 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 713 | 0.130 |
Why?
|
| Wnt Proteins | 1 | 2018 | 191 | 0.130 |
Why?
|
| Cell Communication | 1 | 2018 | 188 | 0.130 |
Why?
|
| Brain Waves | 2 | 2015 | 42 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2022 | 3763 | 0.130 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 644 | 0.130 |
Why?
|
| Electroconvulsive Therapy | 1 | 2018 | 82 | 0.130 |
Why?
|
| Deep Brain Stimulation | 1 | 2022 | 446 | 0.120 |
Why?
|
| Kinetics | 1 | 2018 | 1088 | 0.120 |
Why?
|
| DNA Copy Number Variations | 2 | 2020 | 1029 | 0.120 |
Why?
|
| Depression | 2 | 2023 | 1320 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 321 | 0.120 |
Why?
|
| Cortical Synchronization | 2 | 2015 | 10 | 0.120 |
Why?
|
| Phenanthridines | 1 | 2016 | 3 | 0.120 |
Why?
|
| Flumazenil | 2 | 2015 | 5 | 0.120 |
Why?
|
| Nipecotic Acids | 2 | 2015 | 9 | 0.120 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2016 | 29 | 0.120 |
Why?
|
| GABA Modulators | 2 | 2015 | 12 | 0.120 |
Why?
|
| Nootropic Agents | 1 | 2016 | 27 | 0.120 |
Why?
|
| Dopamine Agonists | 1 | 2016 | 57 | 0.120 |
Why?
|
| Child Development | 1 | 2018 | 266 | 0.110 |
Why?
|
| Computer Simulation | 4 | 2023 | 674 | 0.110 |
Why?
|
| DNA Packaging | 1 | 2014 | 3 | 0.110 |
Why?
|
| Imagination | 1 | 2014 | 13 | 0.110 |
Why?
|
| Pattern Recognition, Visual | 1 | 2014 | 23 | 0.110 |
Why?
|
| Neural Inhibition | 1 | 2015 | 107 | 0.100 |
Why?
|
| Psychometrics | 1 | 2018 | 678 | 0.100 |
Why?
|
| Double-Blind Method | 3 | 2024 | 1626 | 0.100 |
Why?
|
| Machine Learning | 1 | 2018 | 387 | 0.100 |
Why?
|
| Spectrum Analysis | 1 | 2013 | 59 | 0.100 |
Why?
|
| Germ Cells | 1 | 2014 | 201 | 0.100 |
Why?
|
| Urban Population | 1 | 2015 | 287 | 0.100 |
Why?
|
| Synaptic Transmission | 1 | 2015 | 299 | 0.100 |
Why?
|
| Cytokines | 1 | 2019 | 1339 | 0.100 |
Why?
|
| Statistics as Topic | 1 | 2013 | 242 | 0.100 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 3829 | 0.090 |
Why?
|
| Amphetamine | 1 | 2012 | 12 | 0.090 |
Why?
|
| Reaction Time | 1 | 2013 | 152 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1490 | 0.090 |
Why?
|
| Nerve Net | 1 | 2015 | 254 | 0.090 |
Why?
|
| Biomarkers | 2 | 2018 | 3385 | 0.090 |
Why?
|
| Treatment Outcome | 6 | 2025 | 12936 | 0.090 |
Why?
|
| Action Potentials | 1 | 2014 | 476 | 0.090 |
Why?
|
| Carbon Isotopes | 1 | 2012 | 227 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2018 | 2465 | 0.080 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2020 | 897 | 0.080 |
Why?
|
| China | 2 | 2024 | 278 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 597 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2018 | 1928 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2024 | 1216 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 523 | 0.080 |
Why?
|
| Family | 1 | 2013 | 589 | 0.080 |
Why?
|
| Antidepressive Agents | 2 | 2022 | 321 | 0.070 |
Why?
|
| Hospitalization | 1 | 2018 | 1950 | 0.070 |
Why?
|
| Cohort Studies | 1 | 2018 | 5063 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 6797 | 0.070 |
Why?
|
| Age Factors | 1 | 2013 | 2825 | 0.060 |
Why?
|
| Attention | 2 | 2020 | 194 | 0.060 |
Why?
|
| Photic Stimulation | 2 | 2020 | 227 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1939 | 0.060 |
Why?
|
| Child | 2 | 2018 | 26341 | 0.060 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2025 | 27 | 0.060 |
Why?
|
| Neoplasms | 1 | 2020 | 3016 | 0.060 |
Why?
|
| Neurons | 1 | 2014 | 1979 | 0.050 |
Why?
|
| GABA Plasma Membrane Transport Proteins | 2 | 2015 | 16 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 5196 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2018 | 830 | 0.050 |
Why?
|
| United States | 1 | 2019 | 12072 | 0.050 |
Why?
|
| GABAergic Neurons | 2 | 2015 | 75 | 0.050 |
Why?
|
| Light | 1 | 2023 | 166 | 0.050 |
Why?
|
| Electromagnetic Radiation | 1 | 2022 | 4 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 137 | 0.050 |
Why?
|
| Models, Neurological | 2 | 2015 | 212 | 0.050 |
Why?
|
| Citalopram | 1 | 2022 | 29 | 0.040 |
Why?
|
| Positron-Emission Tomography | 2 | 2015 | 279 | 0.040 |
Why?
|
| CA3 Region, Hippocampal | 1 | 2021 | 17 | 0.040 |
Why?
|
| Cyclin E | 1 | 2020 | 30 | 0.040 |
Why?
|
| Verbal Learning | 1 | 2021 | 67 | 0.040 |
Why?
|
| Magnetoencephalography | 1 | 2020 | 44 | 0.040 |
Why?
|
| Aged | 1 | 2019 | 21025 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2020 | 77 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2020 | 87 | 0.040 |
Why?
|
| Parietal Lobe | 1 | 2020 | 46 | 0.040 |
Why?
|
| Loss of Heterozygosity | 1 | 2020 | 123 | 0.040 |
Why?
|
| Clone Cells | 1 | 2020 | 153 | 0.040 |
Why?
|
| CA1 Region, Hippocampal | 1 | 2021 | 68 | 0.040 |
Why?
|
| Oncogene Proteins | 1 | 2020 | 136 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2018 | 17753 | 0.040 |
Why?
|
| Visual Perception | 1 | 2020 | 128 | 0.040 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2021 | 226 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2019 | 236 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2019 | 200 | 0.030 |
Why?
|
| Neuroimaging | 1 | 2021 | 385 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2019 | 412 | 0.030 |
Why?
|
| Organ Size | 1 | 2018 | 407 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 639 | 0.030 |
Why?
|
| Neural Pathways | 1 | 2018 | 270 | 0.030 |
Why?
|
| Neurotransmitter Uptake Inhibitors | 1 | 2015 | 4 | 0.030 |
Why?
|
| Carbon Radioisotopes | 1 | 2015 | 61 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2018 | 587 | 0.030 |
Why?
|
| Pedigree | 1 | 2019 | 1677 | 0.030 |
Why?
|
| Parvalbumins | 1 | 2015 | 38 | 0.030 |
Why?
|
| Psychophysics | 1 | 2014 | 12 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2014 | 54 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2018 | 1246 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2014 | 504 | 0.020 |
Why?
|
| Intellectual Disability | 1 | 2019 | 1089 | 0.020 |
Why?
|
| Electrophysiology | 1 | 2012 | 241 | 0.020 |
Why?
|
| Potassium | 1 | 2012 | 263 | 0.020 |
Why?
|
| Interneurons | 1 | 2012 | 146 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2015 | 496 | 0.020 |
Why?
|
| Ligands | 1 | 2012 | 481 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 761 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 483 | 0.020 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2010 | 119 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 1618 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3359 | 0.020 |
Why?
|
| Animals | 2 | 2015 | 33912 | 0.010 |
Why?
|